OR51E2 and prostate carcinoma: Activation of OR51E2 by specific ligands has been shown to evoke an intracellular calcium response and inhibit prostate cancer cell proliferation, suggesting its potential as a candidate for prostate cancer treatment (Neuhaus et al., 2009, Mermer et al., 2021).